Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common stock, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June 2024, as a material inducement to their employment.